TEL AVIV, Israel, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced participation in a panel titled "Underdiscovered NeuroInnovators" at the Piper Jaffray 27th Annual Healthcare Conference.
| Piper Jaffray 27th Annual Healthcare Conference | |
| Panel Title: | "Underdiscovered NeuroInnovators" |
| Date: | Wednesday, December 2 |
| Time: | 10:00am ET |
| Location: | Lotte New York Palace, New York, NY |
| Presenter: | Dr. Tomer Berkovitz, CFO |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.